Materialise NVNASDAQ: MTLS

Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue.

Materialise (MTLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Materialise NV (NASDAQ:MTLS ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Harriet Fried - Investor Relations-Lippert/Heilshorn & Associates Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Alexander Kramer - Kepler Cheuvreux Jacob Stephan - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q3 2024 Materialise Financial Results Conference Call.

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the third quarter ended September 30, 2024. Highlights – Third Quarter 2024 Total revenue increased 14.2% to 68,652 kEUR compared to 60,130 kEUR for the third quarter of 2023. Gross profit as a percentage of revenue for the third quarter of 2024 was 57.2%, compared to 56.0% for the t.

Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward.

Materialise NV (NASDAQ:MTLS ) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Harriet Fried - Investor Relations-Lippert/Heilshorn & Associates Brigitte de Vet - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Jacob Stephan - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Materialise Financial Results Conference Call.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position.

Materialise reported soft Q3 results, but the stock responded positively anyway, indicating how negative sentiment had become. Weak demand in the Manufacturing segment is a drag, but the Software and Medical segments are still holding up. Macro headwinds are likely to be an ongoing issue, but Materialise's valuation is low. Both relative to peers and based on the company's ability to generate cash.